Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noscapine is a non-sedating benzylisoquinoline alkaloid derived from the opium poppy Papaver somniferum, primarily used as an antitussive (cough suppressant) since the 1950s. It is non-narcotic and lacks addictive or euphoric effects. Its antitussive action is mainly mediated by agonism at sigma receptors, particularly Sigma non-opioid intracellular receptor 1. In addition to its use for cough, noscapine and its derivatives have demonstrated anti-inflammatory, antioxidant, antiangiogenic, antimetastatic, and notable anticancer properties in preclinical studies. These effects are attributed to modulation of microtubule dynamics—noscapine binds to tubulin and disrupts microtubule function—leading to cell cycle arrest at G2/M phase and induction of apoptosis in various cancer cell types. It has also shown neuroprotective potential via sigma receptor activation[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on noscapine.